These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1631 related items for PubMed ID: 19279051

  • 21. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
    Walkty A, Boyd DA, Gravel D, Hutchinson J, McGeer A, Moore D, Simor A, Suh K, Taylor G, Miller M, Mulvey MR, Canadian Nosocomial Infection Surveillance Program.
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):419-24. PubMed ID: 20226332
    [Abstract] [Full Text] [Related]

  • 22. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R, Morosini M, Enright MC, Morrissey I.
    J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
    Allen GP, Hankins CD.
    J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
    [Abstract] [Full Text] [Related]

  • 24. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL.
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India.
    Gaind R, Paglietti B, Murgia M, Dawar R, Uzzau S, Cappuccinelli P, Deb M, Aggarwal P, Rubino S.
    J Antimicrob Chemother; 2006 Dec; 58(6):1139-44. PubMed ID: 17071955
    [Abstract] [Full Text] [Related]

  • 27. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
    Kim JM, Kim JS, Kim N, Jung HC, Song IS.
    J Antimicrob Chemother; 2005 Nov; 56(5):965-7. PubMed ID: 16159928
    [Abstract] [Full Text] [Related]

  • 28. Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations.
    Avrain L, Garvey M, Mesaros N, Glupczynski Y, Mingeot-Leclercq MP, Piddock LJ, Tulkens PM, Vanhoof R, Van Bambeke F.
    J Antimicrob Chemother; 2007 Nov; 60(5):965-72. PubMed ID: 17693451
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure.
    Yan M, Sahin O, Lin J, Zhang Q.
    J Antimicrob Chemother; 2006 Dec; 58(6):1154-9. PubMed ID: 17023497
    [Abstract] [Full Text] [Related]

  • 33. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    Huelves L, Sevillano D, Martínez-Marín C, López-Casla MT, Gracia M, Alou L, del Carmen Ponte M, Prieto J, Soriano F, Spanish Pneumococcal Infection Study Network (G03/103).
    Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
    [Abstract] [Full Text] [Related]

  • 34. Clonal spread of pediatric isolates of ciprofloxacin-resistant, emm type 6 Streptococcus pyogenes.
    Alonso R, Mateo E, Galimand M, Garaizar J, Courvalin P, Cisterna R.
    J Clin Microbiol; 2005 May; 43(5):2492-3. PubMed ID: 15872292
    [Abstract] [Full Text] [Related]

  • 35. High-level fluoroquinolone resistance in a clinical Streptoccoccus pyogenes isolate in Germany.
    Reinert RR, Lütticken R, Al-Lahham A.
    Clin Microbiol Infect; 2004 Jul; 10(7):659-62. PubMed ID: 15214881
    [Abstract] [Full Text] [Related]

  • 36. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC, Wang HB, Sun ZY, Shen ZY.
    Zhonghua Yi Xue Za Zhi; 2003 Mar 10; 83(5):403-7. PubMed ID: 12820918
    [Abstract] [Full Text] [Related]

  • 37. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD.
    Postgrad Med; 2008 Sep 10; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [Abstract] [Full Text] [Related]

  • 38. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
    Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, Fanning S.
    J Antimicrob Chemother; 2006 Dec 10; 58(6):1264-7. PubMed ID: 17018563
    [Abstract] [Full Text] [Related]

  • 39. In vitro development of resistance to DX-619 and other quinolones in enterococci.
    Wickman PA, Black JA, Smith Moland E, Thomson KS, Hanson ND.
    J Antimicrob Chemother; 2006 Dec 10; 58(6):1268-73. PubMed ID: 17062613
    [Abstract] [Full Text] [Related]

  • 40. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
    Davies TA, Yee YC, Goldschmidt R, Bush K, Sahm DF, Evangelista A.
    J Antimicrob Chemother; 2006 Mar 10; 57(3):437-42. PubMed ID: 16431861
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 82.